S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Countries Are Investing Heavily Into Securing Energy Independence (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company

Pacific Biosciences of California Stock Price, News & Analysis (NASDAQ:PACB)

$8.39
-0.53 (-5.94%)
(As of 12/5/2023 ET)
Compare
Today's Range
$8.29
$8.82
50-Day Range
$5.97
$9.03
52-Week Range
$5.74
$14.55
Volume
4.27 million shs
Average Volume
4.12 million shs
Market Capitalization
$2.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.80

Pacific Biosciences of California MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
40.6% Upside
$11.80 Price Target
Short Interest
Bearish
14.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$1.25 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.17) to ($1.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

646th out of 948 stocks

Analytical Instruments Industry

17th out of 27 stocks


PACB stock logo

About Pacific Biosciences of California Stock (NASDAQ:PACB)

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

PACB Stock Price History

PACB Stock News Headlines

Why Is IQVIA (IQV) Up 12.4% Since Last Earnings Report?
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
The Battery Metal Nobody Told You About
According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."
Analyst Expectations for Pacific Biosciences's Future
Piper Sandler Reaffirms Their Hold Rating on Pacific Biosciences (PACB)
PacBio Announces Third Quarter 2023 Financial Results
See More Headlines
Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/15/2024

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
Employees
769
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$11.80
High Stock Price Target
$17.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+40.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-314,250,000.00
Net Margins
-182.34%
Pretax Margin
-188.66%

Debt

Sales & Book Value

Annual Sales
$169.52 million
Book Value
$2.49 per share

Miscellaneous

Free Float
263,700,000
Market Cap
$2.24 billion
Optionable
Optionable
Beta
1.78

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Christian O. Henry M.B.A. (Age 55)
    President, CEO & Director
    Comp: $1.1M
  • Ms. Susan G. KimMs. Susan G. Kim (Age 47)
    Chief Financial Officer
    Comp: $564.87k
  • Mr. Mark Van Oene (Age 50)
    Chief Operating Officer
    Comp: $772.11k
  • Mr. Jeff Eidel (Age 46)
    Chief Commercial Officer
    Comp: $435.62k
  • Dr. Stephen Turner (Age 55)
    Co-Founder & CTO
    Comp: $341.25k
  • Ms. Michele Farmer CPA (Age 43)
    VP & Chief Accounting Officer
  • Dr. Jonas Korlach Ph.D.
    Chief Scientific Officer
  • Trevin Rard
    Head of Investor Relations
  • Dr. Brett Atkins J.D.
    Ph.D., General Counsel & Corporate Secretary
  • Ms. Natalie Welch
    Chief People Officer














PACB Stock Analysis - Frequently Asked Questions

Should I buy or sell Pacific Biosciences of California stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PACB shares.
View PACB analyst ratings
or view top-rated stocks.

What is Pacific Biosciences of California's stock price target for 2024?

11 brokers have issued 12-month price objectives for Pacific Biosciences of California's stock. Their PACB share price targets range from $8.00 to $17.00. On average, they expect the company's stock price to reach $11.80 in the next year. This suggests a possible upside of 40.6% from the stock's current price.
View analysts price targets for PACB
or view top-rated stocks among Wall Street analysts.

How have PACB shares performed in 2023?

Pacific Biosciences of California's stock was trading at $8.18 at the start of the year. Since then, PACB shares have increased by 2.6% and is now trading at $8.39.
View the best growth stocks for 2023 here
.

When is Pacific Biosciences of California's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our PACB earnings forecast
.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its quarterly earnings results on Monday, October, 30th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. The biotechnology company had revenue of $55.70 million for the quarter, compared to analyst estimates of $48.76 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 43.39% and a negative net margin of 182.34%. The business's quarterly revenue was up 72.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.32) EPS.

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.90%), Sumitomo Mitsui Trust Holdings Inc. (5.37%), FMR LLC (1.73%), Bank of New York Mellon Corp (1.76%), Lord Abbett & CO. LLC (1.37%) and Northern Trust Corp (1.05%). Insiders that own company stock include Christian O Henry, Eric Schaefer, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Michele Farmer, Oene Mark Van, Peter Fromen, Susan G Kim and William W Ericson.
View institutional ownership trends
.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Pacific Biosciences of California have any subsidiaries?
The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.
Read More
This page (NASDAQ:PACB) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -